BF Biosciences Limited (BFBL), a leading pharmaceutical company in Pakistan, has entered into a contract manufacturing and supply agreement with Lucky Core Industries Limited (LCI). The announcement was made by Ferozsons Laboratories Limited, the parent company of BFBL, in a notice to the Pakistan Stock Exchange (PSX) on Wednesday.

According to the notice, BFBL will manufacture and supply the products “Esopase IV 40 mg” and “Etipro IV 40 mg” under the new agreement with LCI. BFBL, a joint venture between Ferozsons Laboratories Limited and Argentina’s Bagó Group, specializes in the import, manufacturing, marketing, and distribution of pharmaceutical products.

In recent developments, BFBL successfully launched a human insulin product under the brand name “Ferulin” last month. The company is also planning an initial public offering (IPO) on the PSX, to raise at least Rs. 1.375 billion ($4.94 million) by issuing 25 million shares at a floor price of Rs55 per share.